DOXYCYCLINE CAPSULES USP Susceptibility Testing Methods Table 2. Acceptable Quality Control Ranges for Susceptibility Testing Rx only When available, the clinical microbiology laboratory should provide cumulative For Doxycycline and Tetracycline results of in vitro susceptibility test results for antimicrobial drugs used in local To reduce the development of drug-resistant bacteria and maintain the effective- Minimal hospitals and practice areas as periodic reports that describe the susceptibility Zone Agar ness of doxycycline capsules and other antibacterial drugs, doxycycline capsules Inhibitory profile of nosocomial and community-acquired pathogens. These reports should QC Strain Diameter Dilution should be used only to treat or prevent infections that are proven or strongly Concentration aid the physician in selecting the most effective antimicrobial. (mm) (mcg/mL) suspected to be caused by bacteria. (mcg/mL) Dilution Techniques DESCRIPTION Quantitative methods are used to determine antimicrobial minimum inhibitory con- Enterococcus faecalis Doxycycline Capsules USP is a broad-spectrum antibacterial synthetically derived centrations (MICs). These MICs provide estimates of the susceptibility of bacteria ATCC 29212 from oxytetracycline. Doxycycline 150 mg, 100 mg and 50 mg capsules contain to antimicrobial compounds. The MICs should be determined using a standardized Doxycycline 2-8 - - doxycycline monohydrate equivalent to 150 mg, 100 mg or 50 mg of doxycycline test method (broth and/or agar).1,2,4,6,7 The MIC values should be interpreted Tetracycline 8-32 - - for oral administration. The chemical designation of the light-yellow crystalline according to criteria provided in Table 1. Escherichia coli ATCC 25922 powder is alpha-6-deoxy-5-oxytetracycline. Diffusion Techniques Doxycycline 0.5-2 18-24 - Structural formula: Quantitative methods that require measurement of zone diameters can also pro- Tetracycline 0.5-2 18-25 - vide reproducible estimates of the susceptibility of bacteria to antimicrobial com- Eggerthella lenta pounds. The zone size should be determined using a standard test method.1,3,4 ATCC 43055 This procedure uses paper disks impregnated with 30 mcg doxycycline to test Doxycycline 2-16 - - the susceptibility of microorganisms to doxycycline. The disk diffusion interpretive Haemophilus influenzae ATCC criteria are provided in Table 1. 49247 Anaerobic Techniques Tetracycline 4-32 14-22 - C22H24N2O8•H2O M.W. = 462.45 For anaerobic bacteria, the susceptibility to doxycycline can be determined by Neisseria gonorrhoeae Doxycycline Capsules USP has a high degree of lipid solubility and a low affinity a standardized test method.1,5 The MIC values obtained should be interpreted ATCC 49226 for calcium binding. It is highly stable in normal human serum. Doxycycline will not according to the criteria provided in Table 1. Tetracycline - 30-42 0.25-1 degrade into an epianhydro form. Staphylococcus aureus ATCC Table 1: Susceptibility Test Interpretive Criteria for Doxycycline and 25923 Inactive ingredients include: colloidal silicon dioxide, gelatin, magnesium stea- Tetracycline rate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide. In Doxycycline - 23-29 - addition, the 50 mg strength contains FD&C Yellow #6 and D&C Yellow #10. The Bacteria* Minimal Zone Diameter Agar Dilution Tetracycline - 24-30 - 100 mg strength also contains black iron oxide, red iron oxide and yellow iron Inhibitory (mm) (mcg/mL) Staphylococcus aureus ATCC oxide. The 150 mg strength includes FD&C Red #40 and FD&C Yellow #6. Concentration 29213 (mcg/mL) Doxycycline 0.12-0.5 - - CLINICAL PHARMACOLOGY Tetracycline 0.12-1 - - S I R S I R S I R Tetracyclines are readily absorbed and are bound to plasma proteins in varying Streptococcus pneumoniae degrees. They are concentrated by the liver in the bile and excreted in the urine Acinetobacter spp. ATCC 49619

and feces at high concentrations in a biologically active form. Doxycycline is virtu- Doxycycline ≤4 8 ≥16 ≥13 10-12 ≤9 - - - Doxycycline 0.015-0.12 25-34 - 010726-16 ally completely absorbed after oral administration. Tetracycline ≤4 8 ≥16 ≥15 12-14 ≤11 - - - Tetracycline 0.06-0.5 27-31 - Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers Anaerobes Bacteroides fragilis averaged the following serum concentration values: Tetracycline ------≤4 8 ≥16 ATCC 25285 Tetracycline - - 0.125-0.5 Time Bacillus anthracis† Bacteroides thetaiotaomicron (hr): 0.5 1.0 1.5 2.0 3.0 4.0 8.0 12.0 24.0 48.0 72.0 Doxycycline ≤1 ------ATCC 29741 Doxycycline 2-8 - - Conc. Tetracycline ≤1 ------Tetracycline - - 8-32 (mcg/mL): 1.02 2.26 2.67 3.01 3.16 3.03 2.03 1.62 0.95 0.37 0.15 Brucella species† Mycoplasma pneumoniae ATCC Doxycycline ≤1 ------29342 Average Observed Values Tetracycline ≤1 ------Tetracycline 0.06-0.5 - 0.06-0.5 Maximum Concentration 3.61 mcg/mL (± 0.9 sd) Ureaplasma urealyticum ATCC Time of Maximum Concentration 2.60 hr (± 1.10 sd) Enterobacteriaceae 33175 Elimination Rate Constant 0.049 per hr (± 0.030 sd) Doxycycline ≤4 8 ≥16 ≥14 11-13 ≤10 - - - Tetracycline - - ≥8 Half-Life 16.33 hr (± 4.53 sd) Tetracycline ≤4 8 ≥16 ≥15 12-14 ≤11 - - - *ATCC is the American Type Culture Collection Franciscella tularensis† Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with INDICATIONS AND USAGE Doxycycline ≤4 ------normal function (creatinine clearance about 75 mL/min). This percentage excretion To reduce the development of drug-resistant bacteria and maintain the effec- DOXYCYCLINE may fall as low as 1 to 5%/72 hours in individuals with severe renal insufficiency Tetracycline ≤4 ------CAPSULES USP tiveness of doxycycline capsules USP and other antibacterial drugs, doxycycline (creatinine clearance below 10 mL/min). Studies have shown no significant differ- R 01/2020 Haemophilus influenzae capsules USP should be used only to treat or prevent infections that are proven ence in serum half-life of doxycycline (range 18 to 22 hours) in individuals with or strongly suspected to be caused by susceptible bacteria. When culture and normal and severely impaired renal function. Tetracycline ≤2 4 ≥8 ≥29 26-28 ≤25 - - - susceptibility information are available, they should be considered in selecting or Hemodialysis does not alter serum half-life. Mycoplasma modifying antibacterial therapy. In the absence of such data, local epidemiology † and susceptibility patterns may contribute to the empiric selection of therapy. Population pharmacokinetic analysis of sparse concentration-time data of doxycy- pneumoniae 010726-16 cline following standard of care intravenous and oral dosing in 44 pediatric patients Tetracycline ------≤2 - - Doxycycline Capsules USP is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, (2-18 years of age) showed that allometrically –scaled clearance (CL) of doxycy- Neisseria gonorrhoeae‡ cline in pediatric patients ≥2 to ≤8 years of age (median [range] 3.58 [2.27-10.82] rickettsialpox, and tick fevers caused by Rickettsiae. L/h/70 kg, N =11) did not differ significantly from pediatric patients >8 to 18 years Tetracycline - - - ≥38 31-37 ≤30 ≤0.25 0.5-1 ≥2 Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. of age (3.27 [1.11-8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, Norcardiae and other body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median Psittacosis (ornithosis) caused by Chlamydophila psittaci. aerobic Actinomyces Trachoma caused by Chlamydia trachomatis, although the infectious agent [range] 0.071 [0.041-0.202] L/kg/h, N=10) did not differ significantly from those † >8 to 18 years of age (0.081 [0.035-0.126] L/kg/h, N=8). In pediatric patients species is not always eliminated as judged by immunofluorescence. weighing >45 kg, no clinically significant differences in body weight normalized Doxycycline ≤1 2-4 ≥8 ------Inclusion conjunctivitis caused by Chlamydia trachomatis. doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=1) Uncomplicated urethral, endocervical or rectal infections in adults caused by and those >8 to 18 years of age (0.044 [0.014-0.121] L/kg/h, N=25). No clinically Streptococcus Chlamydia trachomatis. significant difference in CL between oral and IV dosing was observed in the small pneumoniae Nongonococcal urethritis caused by Ureaplasma urealyticum. cohort of pediatric patients who received the oral (N=19) or IV (N=21) formulation Doxycycline ≤0.25 0.5 ≥1 ≥28 25-27 <24 - - - Relapsing fever due to Borrelia recurrentis. alone. Tetracycline ≤1 2 ≥4 ≥28 25-27 ≤24 - - - Doxycycline Capsules USP is also indicated for the treatment of infections caused Microbiology: Vibrio cholerae by the following gram-negative microorganisms: Mechanism of Action Chancroid caused by Haemophilus ducreyi. Doxycycline ≤4 8 ≥16 ------Plague due to Yersinia pestis. Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribo- Tetracycline ≤4 8 ≥16 ------somal subunit. Doxycycline has bacteriostatic activity against a broad range of Tularemia due to Francisella tularensis. Gram-positive and Gram-negative bacteria. Yersinia pestis Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Resistance Doxycycline ≤4 8 ≥16 ------Brucellosis due to Brucella species (in conjunction with streptomycin). Cross resistance with other tetracyclines is common. Tetracycline ≤4 8 ≥16 ------Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Antimicrobial Activity Ureaplasma urealyticum Doxycycline has been shown to be active against most isolates of the following Tetracycline ------≤1 - ≥2 Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. microorganisms, both in vitro and in clinical infections (see INDICATIONS AND * Organisms susceptible to tetracycline are also considered susceptible to USAGE). doxycycline. However, some organisms that are intermediate or resistant to Doxycycline Capsules USP is indicated for treatment of infections caused by the Gram-Negative Bacteria tetracycline may be susceptible to doxycycline. following gram-negative microorganisms, when bacteriologic testing indicates Acinetobacter species † The current absence of resistance isolates precludes defining any results other appropriate susceptibility to the drug: Bartonella bacilliformis than “Susceptible”. If isolates yielding MIC results other than susceptible, they Escherichia coli Brucella species should be submitted to a reference laboratory for further testing. Enterobacter aerogenes Campylobacter fetus ‡ Gonococci with 30 mcg tetracycline disk zone diameters of less than Shigella species Enterobacter aerogenes 19 mm usually indicate a plasmid-mediated tetracycline resistant Neisseria Acinetobacter species Escherichia coli gonorrhoeae isolate. Resistance in these strains should be confirmed by a Respiratory tract infections caused by Haemophilus influenzae. Francisella tularensis dilution test (MIC ≥ 16 mcg per mL). Respiratory tract and urinary tract infections caused by Klebsiella species. Haemophilus ducreyi Doxycycline Capsules USP is indicated for treatment of infections caused by Haemophilus influenzae A report of Susceptible (S) indicates that the antimicrobial is likely to inhibit growth the following gram-positive microorganisms, when bacteriologic testing indicates Klebsiella granulomatis of the microorganism if the antimicrobial drug reaches the concentration usually appropriate susceptibility to the drug: Klebsiella species achievable at the site of infection. A report of Intermediate (I) indicates that the Upper respiratory infections caused by Streptococcus pneumoniae. Neisseria gonorrhoeae result should be considered equivocal, and, if the microorganism is not fully sus- Anthrax due to Bacillus anthracis, including inhalational anthrax (post- Shigella species ceptible to alternative, clinically feasible drugs, the test should be repeated. This exposure); to reduce the incidence or progression of disease following Vibrio cholerae category implies possible clinical applicability in body sites where the drug product exposure to aerosolized Bacillus anthracis. Yersinia pestis is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled When penicillin is contraindicated, doxycycline is an alternative drug in the treat- Gram-Positive Bacteria technical factors from causing major discrepancies in interpretation. A report of ment of the following infections: Bacillus anthracis Resistant (R) indicates that the antimicrobial drug is not likely to inhibit growth of Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Listeria monocytogenes the microorganism if the antimicrobial drug reaches the concentrations usually Syphilis caused by Treponema pallidum. Streptococcus pneumoniae achievable at the infection site; other therapy should be selected. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anaerobic Bacteria Quality Control Clostridium species Vincent’s infection caused by Fusobacterium fusiforme. Standardized susceptibility test procedures require the use of laboratory con- Fusobacterium fusiforme Actinomycosis caused by Actinomyces israelii. trols to monitor and ensure the accuracy and precision of the supplies and Propionibacterium acnes Infections caused by Clostridium species. reagents used in the assay, and the techniques of the individuals performing the Other Bacteria test.1,2,3,4,5,6,7 In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Nocardiae and other Actinomyces species Standard doxycycline and tetracycline powders should provide the following range In severe acne, doxycycline may be useful adjunctive therapy. Borrelia recurrentis of MIC values noted in . For the diffusion technique using the 30 mcg Chlamydophila psittaci Table 2 CONTRAINDICATIONS doxycycline disk or 30 mcg tetracycline disk, the criteria noted in should Chlamydia trachomatis Table 2 This drug is contraindicated in persons who have shown hypersensitivity to any be achieved. Mycoplasma pneumoniae of the tetracyclines. Rickettsiae Treponema pallidum WARNINGS Treponema pallidum subspecies pertenue The use of drugs of the tetracycline class, including doxycycline, during tooth Ureaplasma urealyticum development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse Parasites reaction is more common during long-term use of the drugs but has been observed Balantidium coli following repeated short-term courses. Enamel hypoplasia has also been reported. Entamoeba species Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening no apparent effect on the fertility of female rats. Effect on male fertility has not Primary and secondary syphilis: 300 mg a day in divided doses for at least conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there been studied. 10 days. are no alternative therapies. Pregnancy: Uncomplicated urethral, endocervical, or rectal infection in adults caused Clostridium difficile associated diarrhea (CDAD) has been reported with use of Teratogenic Effects. by Chlamydia trachomatis: 100 mg, by mouth, twice a day for at least 7 days. nearly all antibacterial agents, including doxycycline capsules, and may range Pregnancy Category D: There are no adequate and well-controlled studies on the use of doxycycline in Nongonococcal urethritis caused by C. trachomatis and U. urealyticum: 100 in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents mg, by mouth, twice a day for at least 7 days. alters the normal flora of the colon leading to overgrowth of C. difficile. pregnant short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice C. difficile produces toxins A and B which contribute to the development of CDAD. such as that proposed for treatment of anthrax exposure. An expert review of a day for at least 10 days. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, published data on experiences with doxycycline use during pregnancy by TERIS as these infections can be refractory to antimicrobial therapy and may require Inhalational anthrax (post-exposure): - the Teratogen Information System - concluded that therapeutic doses during ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days. colectomy. CDAD must be considered in all patients who present with diarrhea fol- pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and lowing antibiotic use. Careful medical history is necessary since CDAD has been quality of data were assessed as limited to fair), but the data are insufficient to CHILDREN: weighing less than 45 kg 2.2 mg/kg of body weight, by mouth, twice reported to occur over two months after the administration of antibacterial agents. state that there is no risk.8 a day for 60 days. Children weighing 45 kg or more should receive the adult dose. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against A case-control study (18,515 mothers of infants with congenital anomalies and C. difficile may need to be discontinued. Appropriate fluid and electrolyte man- HOW SUPPLIED 32,804 mothers of infants with no congenital anomalies) shows a weak but Doxycycline Capsules USP 50 mg have a buff opaque cap printed “par 726” agement, protein supplementation, antibiotic treatment of C. difficile, and surgical marginally statistically significant association with total malformations and use evaluation should be instituted as clinically indicated. in brown ink/white opaque body printed “par 726” in brown ink. Each capsule of doxycycline anytime during pregnancy. (Sixty-three (0.19%) of the controls contains doxycycline monohydrate equivalent to 50 mg of doxycycline. They are Intracranial hypertension (IH, pseudotumor cerebri) has been associated with and 56 (0.30%) of the cases were treated with doxycycline.) This association supplied as follows: the use of tetracyclines including doxycycline capsules. Clinical manifestations was not seen when the analysis was confined to maternal treatment during the Bottles of 100 NDC 49884-726-01 of IH include headache, blurred vision, diplopia, and vision loss; papilledema period of organogenesis (i.e., in the second and third months of gestation) with can be found on fundoscopy. Women of childbearing age who are overweight the exception of a marginal relationship with neural tube defect based on only Doxycycline Capsules USP 100 mg have a brown opaque cap printed “par 727” or have a history of IH are at greater risk for developing tetracycline associated two exposed cases.9 in white ink/white opaque body printed “par 727” in brown ink. Each capsule IH. Concomitant use of isotretinoin and doxycycline capsules should be avoided A small prospective study of 81 pregnancies describes 43 pregnant women treated contains doxycycline monohydrate equivalent to 100 mg of doxycycline. They are because isotretinoin is also known to cause pseudotumor cerebri. for 10 days with doxycycline during early first trimester. All mothers reported their supplied as follows: Although IH typically resolves after discontinuation of treatment, the possibility exposed infants were normal at 1 year of age.10 Bottles of 50 NDC 49884-727-03 Bottles of 250 NDC 49884-727-04 for permanent visual loss exists. If visual disturbance occurs during treatment, Labor and Delivery: prompt ophthalmologic evaluation is warranted. Since intracranial pressure can The effect of tetracyclines on labor and delivery is unknown. Doxycycline Capsules USP 150 mg have a peach opaque cap printed “par” in remain elevated for weeks after drug cessation patients should be monitored until black ink/peach opaque body printed “305” in black ink. Each capsule contains they stabilize. Nursing Mothers: Tetracyclines are excreted in human milk, however, the extent of absorption of tet- doxycycline monohydrate equivalent to 150 mg of doxycycline. They are supplied All tetracyclines form a stable calcium complex in any bone-forming tissue. racyclines, including doxycycline, by the breastfed infant is not known. Short-term as follows: A decrease in the fibula growth rate has been observed in prematures given oral use by lactating women is not necessarily contraindicated; however, the effects Bottles of 60 NDC 49884-305-02 tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be of prolonged exposure to doxycycline in breast milk are unknown.11 Because of reversible when the drug was discontinued. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room the potential for adverse reactions in nursing infants from doxycycline, a decision Temperature]. Protect from light. Results of animal studies indicate that tetracyclines cross the placenta, are found should be made whether to discontinue nursing or to discontinue the drug, taking in fetal tissues, and can have toxic effects on the developing fetus (often related to into account the importance of the drug to the mother. (See WARNINGS.) DISPENSE IN A TIGHT LIGHT RESISTANT CONTAINER AS DEFINED IN THE retardation of skeletal development). Evidence of embryo toxicity has been noted USP/NF. Pediatric Use: in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be Because of the effects of drugs of the tetracycline-class, on tooth development ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY apprised of the potential hazard to the fetus. and growth, use doxycycline in pediatric patients 8 years of age or less only when Hyperpigmentation of the thyroid has been produced by members of the tetra- the potential benefits are expected to outweigh the risks in severe or life-threat- cycline class in the following species: in rats by oxytetracycline, doxycycline, The antianabolic action of the tetracyclines may cause an increase in BUN. Stud- ening conditions (e.g., anthrax, Rocky mountain spotted fever), particularly tetracycline PO , and methacycline; in minipigs by doxycycline, minocycline, ies to date indicate that this does not occur with the use of doxycycline in patients 4 when there are no alternative therapies (see WARNINGS and DOSAGE AND tetracycline PO4, and methacycline; in dogs by doxycycline and minocycline; in with impaired renal function. ADMINISTRATION). monkeys by minocycline. Photosensitivity manifested by an exaggerated sunburn reaction has been Minocycline, tetracycline PO , methacycline, doxycycline, tetracycline base, observed in some individuals taking tetracyclines. Patients apt to be exposed to ADVERSE REACTIONS 4 Due to oral doxycycline’s virtually complete absorption, side effects to the lower oxytetracycline HCl and tetracycline HCl were goitrogenic in rats fed a low iodine direct sunlight or ultraviolet light should be advised that this reaction can occur diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. with tetracycline drugs, and treatment should be discontinued at the first evidence bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines. Administration of minocycline also produced a large goiter with high radioiodine of skin erythema. uptake in rats fed a relatively high iodine diet. Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, PRECAUTIONS enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital Treatment of various animal species with this class of drugs has also resulted General: region, and pancreatitis. Hepatotoxicity has been reported. These reactions have in the induction of thyroid hyperplasia in the following: in rats and dogs (mino- As with other antibacterial preparations, use of this drug may result in overgrowth been caused by both the oral and parenteral administration of tetracyclines. cycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). of non-susceptible organisms, including fungi. If superinfection occurs, doxycy- Rare instances of esophagitis and esophageal ulcerations have been reported Adrenal gland hyperplasia has been observed in goats and rats treated with cline capsules should be discontinued and appropriate therapy instituted. in patients receiving capsule and tablet forms of drugs in the tetracycline class. oxytetracycline. Incision and drainage or other surgical procedures should be performed in con- Most of these patients took medications immediately before going to bed. (See REFERENCES DOSAGE AND ADMINISTRATION.) junction with antibacterial therapy when indicated. 1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards Prescribing doxycycline capsules in the absence of a proven or strongly suspected Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic for Antimicrobial Susceptibility Testing; Twenty-seventh Informational Supple- bacterial infection or a prophylactic indication is unlikely to provide benefit to the epidermal necrolysis, and erythema multiforme have been reported. Exfoliative ment, CLSI document M100-S27 [2017]. CLSI document M100S23, Clinical patient and increases the risk of the development of drug-resistant bacteria. dermatitis has been reported but is uncommon. Photosensitivity is discussed Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne above. (See WARNINGS.) Pennsylvania 19087, USA. Information for Patients: All patients taking doxycycline should be advised: Renal Toxicity: Rise in BUN has been reported and is apparently dose related. 2. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Anti- -to avoid excessive sunlight or artificial ultraviolet light while receiving doxy- (See WARNINGS.) microbial Susceptibility Tests for Bacteria that Grow Aerobically; Approved cycline and to discontinue therapy if phototoxicity (e.g., skin eruptions, etc.) Hypersensitivity Reactions: Urticaria, angioneurotic edema, anaphylaxis, ana- Standard – Tenth Edition. CLSI document M07-A10 [2015], Clinical Laboratory occurs. Sunscreen or sunblock should be considered. (See WARNINGS.) phylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania -to drink fluids liberally along with doxycycline to reduce the risk of esophageal lupus erythematosus. 19087, USA. irritation and ulceration. (See .) ADVERSE REACTIONS Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have 3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for -that the absorption of tetracyclines is reduced when taken with foods, espe- been reported with tetracyclines. Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard - Twelfth cially those which contain calcium. However, the absorption of doxycycline is Other: Intracranial hypertension (IH, pseudotumor cerebri) has been associated Edition. CLSI Document M02-A12 [2015], Clinical Laboratory Standards Insti- not markedly influenced by simultaneous ingestion of food or milk. (See Drug with the use of tetracyclines. (See PRECAUTIONS-General.) tute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA. Interactions.) -that the absorption of tetracyclines is reduced when taking bismuth subsalicy- When given over prolonged periods, tetracyclines have been reported to produce 4. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial late. (See Drug Interactions.) brown-black microscopic discoloration of the thyroid gland. No abnormalities of Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious thyroid function are known to occur. Bacteria; Approved Guideline – Third Edition. CLSI Document M45-A3 [2015], -not to use outdated or poorly stored doxycycline. Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, -that the use of doxycycline might increase the incidence of vaginal candidiasis. OVERDOSAGE Wayne Pennsylvania 19087, USA. Diarrhea is a common problem caused by antibiotics which usually ends when In case of overdosage, discontinue medication, treat symptomatically and institute the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, supportive measures. Dialysis does not alter serum half-life, and it would not be of 5. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial patients can develop watery and bloody stools (with or without stomach cramps benefit in treating cases of overdosage. Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Eighth Edi- and fever) even as late as two or more months after having taken the last dose tion. CLSI Document M11-A8 [2012], Clinical Laboratory Standards Institute, of the antibiotic. If this occurs, patients should contact their physician as soon as DOSAGE AND ADMINISTRATION 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA. possible. THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCY- CLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING 6. Clinical and Laboratory Standards Institute (CLSI). Methods for Mycobacteria, Patients should be counseled that antibacterial drugs including doxycycline THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE Nocardiae, and Other Aerobic Actinomycetes; Approved Standard – Second capsules should only be used to treat bacterial infections. They do not treat viral OF SIDE EFFECTS. Edition. CLSI Document M24-A2 [2011], Clinical Laboratory Standards Insti- infections (e.g., the common cold). When doxycycline capsules is prescribed to tute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA. treat a bacterial infection, patients should be told that although it is common to Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment feel better early in the course of therapy, the medication should be taken exactly (administered 100 mg every 12 hours or 50 mg every 6 hours) followed by a 7. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial as directed. Skipping doses or not completing the full course of therapy may (1) maintenance dose of 100 mg/day. The maintenance dose may be administered Susceptibility Testing for Human Mycoplasmas; Approved Guideline. CLSI decrease the effectiveness of the immediate treatment and (2) increase the likeli- as a single dose or as 50 mg every 12 hours. In the management of more severe Document M43-A [2011], Clinical Laboratory Standards Institute, 950 West hood that bacteria will develop resistance and will not be treatable by doxycycline infections (particularly chronic infections of the urinary tract), 100 mg every Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA. 12 hours is recommended. or other antibacterial drugs in the future. 8. Friedman JM and Polifka JE. Teratogenic Effects of Drugs. A Resource for Laboratory Tests: Pediatric Patients: Clinicians (TERIS). Baltimore, MD: The Johns Hopkins University Press: In venereal disease when coexistent syphilis is suspected, a dark-field examina- For all pediatric patients weighing less than 45 kg with severe or life-threatening 2000: 149-195. tion should be done before treatment is started and the blood serology repeated infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended monthly for at least four months. dosage is 2.2 mg/kg of body weight administered every 12 hours. Children 9. Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. Obstet weighing 45 kg or more should receive the adult dose (see WARNINGS and Gynecol 1997; 89: 524-528. In long-term therapy, periodic laboratory evaluations of organ systems, including PRECAUTIONS). hematopoietic, renal, and hepatic studies should be performed. 10. Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecu- For pediatric patients with less severe disease (greater than 8 years of age and tive pregnancies: a prospective study. Int J Fertil 1980; 25: 315-317. Drug Interactions: weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of Because tetracyclines have been shown to depress plasma prothrombin activity, body weight divided into two doses on the first day of treatment, followed by a 11. Hale T. Medications and Mothers Milk. 9th edition. Amarillo, TX: Pharmasoft patients who are on anticoagulant therapy may require downward adjustment of maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or Publishing 2000; 225-226. their anticoagulant dosage. divided into twice daily doses). For pediatric patients weighing over 45 kg, the Manufactured by: usual adult dose should be used. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it PAR PHARMACEUTICAL is advisable to avoid giving tetracyclines in conjunction with penicillin. The therapeutic antibacterial serum activity will usually persist for 24 hours follow- Chestnut Ridge, NY 10977 Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, ing recommended dosage. or magnesium, and iron-containing preparations. When used in streptococcal infections, therapy should be continued for 10 days. Revised: 01/2020 OS726-01-1-16 Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline. Administration of adequate amounts of fluid along with capsule and tablet forms The concurrent use of tetracycline and methoxyflurane has been reported to result of drugs in the tetracycline class is recommended to wash down the drugs in fatal renal toxicity. and reduce the risk of esophageal irritation and ulceration (see ADVERSE REACTIONS). Concurrent use of tetracycline may render oral contraceptives less effective. If gastric irritation occurs, it is recommended that doxycycline be given with food Drug/Laboratory Test Interactions: or milk. The absorption of doxycycline is not markedly influenced by simultaneous False elevations of urinary catecholamine levels may occur due to interference ingestion of food or milk. with the fluorescence test. Studies to date have indicated that administration of doxycycline at the usual Carcinogenesis, Mutagenesis, Impairment of Fertility: recommended doses does not lead to excessive accumulation of doxycycline in Long-term studies in animals to evaluate the carcinogenic potential of doxycycline patients with renal impairment. have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with related antibacterial, oxytetracycline (adrenal and pituitary Uncomplicated gonococcal infections in adults (except anorectal infections tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit of doxycycline have not been conducted, positive results in in vitro mammalian cell dose, administer 300 mg stat followed in one hour by a second 300 mg dose. assays have been reported for related antibacterial (tetracycline, oxytetracycline). Acute epididymo-orchitis caused by N. gonorrhoeae: 100 mg, by mouth, twice Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had a day for at least 10 days.